Erlotinib News and Research

RSS
Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.
Targeted cancer therapies: Another step forward

Targeted cancer therapies: Another step forward

Lung cancer drug approved for treating pancreatic cancer

Lung cancer drug approved for treating pancreatic cancer

Tarceva should be tested as front-line therapy for older lung cancer patients

Tarceva should be tested as front-line therapy for older lung cancer patients

Mutations in the targets of designer drugs critically influence their effectiveness

Mutations in the targets of designer drugs critically influence their effectiveness

Erlotinib increases survival in patients with advanced non-small cell lung cancer

Erlotinib increases survival in patients with advanced non-small cell lung cancer

Study examines biomarkers for response to erlotinib in glioma

Study examines biomarkers for response to erlotinib in glioma

First advance in pancreatic cancer treatment in a decade offers new hope

First advance in pancreatic cancer treatment in a decade offers new hope

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Study describes the first known mutation to occur in lung cancer patients who have never smoked

Study describes the first known mutation to occur in lung cancer patients who have never smoked

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

FDA approves Tarceva (erlotinib)

FDA approves Tarceva (erlotinib)

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

New Drug Application with the U.S. Food and Drug Administration for Tarceva

New Drug Application with the U.S. Food and Drug Administration for Tarceva

Drug Tarceva improves survival chance for patients with advanced lung cancer

Drug Tarceva improves survival chance for patients with advanced lung cancer

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Avastin study shows significant improvement in patients with metastatic colorectal cancer

New cancer drug Tarceva - a breakthrough with significant survival benefit in patients with advanced lung cancer

New cancer drug Tarceva - a breakthrough with significant survival benefit in patients with advanced lung cancer